Moderna and Merck's Personalized Cancer Vaccine Breakthrough

Moderna and Merck have achieved a breakthrough in cancer medicine by developing a personalized mRNA treatment for melanoma. Unlike traditional vaccines made en masse, each dose of this new treatment is designed from the genetic fingerprint of an individual patient's tumour.

This marks the first time a cancer vaccine has been tailored to a specific patient's needs. The companies' achievement is significant, as it could potentially revolutionize the way cancer treatment is approached.

The process works by analyzing the genetic material of a patient's tumour and creating a unique medicine that targets those specific cells. This approach differs from traditional treatments, which are often one-size-fits-all.